Submit Search
Upload
Nejm Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
•
1 like
•
226 views
Bhargav Kiran
Follow
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
Read less
Read more
Health & Medicine
Report
Share
Report
Share
1 of 11
Download now
Download to read offline
Recommended
Effects of aspirin for primary prevention in persons with Diabetes mellitus
Effects of aspirin for primary prevention in persons with Diabetes mellitus
Shadab Ahmad
Journal club 1
Journal club 1
Bhargav Kiran
Rivaroxaban with or without aspirin in patients with stable peripheral or car...
Rivaroxaban with or without aspirin in patients with stable peripheral or car...
Bhargav Kiran
CLEVER Final Manuscript_JACC_17Mar2015
CLEVER Final Manuscript_JACC_17Mar2015
Ingrid Abrahamsen, MS, CCRP
Res update final
Res update final
katejohnpunag
SSHC Journal Club presentation on the The Journal of Infectious Disease Volu...
SSHC Journal Club presentation on the The Journal of Infectious Disease Volu...
Sydney Sexual Health Centre
Journal club: CheckMate025 trial
Journal club: CheckMate025 trial
Ahmed A. Karar Ali
Journal Club
Journal Club
visheshrohatgi
Recommended
Effects of aspirin for primary prevention in persons with Diabetes mellitus
Effects of aspirin for primary prevention in persons with Diabetes mellitus
Shadab Ahmad
Journal club 1
Journal club 1
Bhargav Kiran
Rivaroxaban with or without aspirin in patients with stable peripheral or car...
Rivaroxaban with or without aspirin in patients with stable peripheral or car...
Bhargav Kiran
CLEVER Final Manuscript_JACC_17Mar2015
CLEVER Final Manuscript_JACC_17Mar2015
Ingrid Abrahamsen, MS, CCRP
Res update final
Res update final
katejohnpunag
SSHC Journal Club presentation on the The Journal of Infectious Disease Volu...
SSHC Journal Club presentation on the The Journal of Infectious Disease Volu...
Sydney Sexual Health Centre
Journal club: CheckMate025 trial
Journal club: CheckMate025 trial
Ahmed A. Karar Ali
Journal Club
Journal Club
visheshrohatgi
Journal club 20 10-2016
Journal club 20 10-2016
Amit Verma
RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...
RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...
Sociedad Latinoamericana de Cardiología Intervencionista
Nov journal watch
Nov journal watch
katejohnpunag
Chest pain scores
Chest pain scores
Kristopher Maday
Journal club 1
Journal club 1
Bhargav Kiran
Ascend trial diabetes
Ascend trial diabetes
SATYA PRASAD Mahapatra
Journal club on Antiypertensives
Journal club on Antiypertensives
Dr.Kiran A Kantanavar
Feb 2015 journal watch with links
Feb 2015 journal watch with links
katejohnpunag
Journal club
Journal club
STANMED
Journal club
Journal club
LPS Institute of Cardiology Kanpur UP India
Heparin with ua
Heparin with ua
Virginia Mason Internal Medicine Residency
Intensive Insulin Therapy In The Medical Icu
Intensive Insulin Therapy In The Medical Icu
NadSamm
HNDM proceedings of November 2016,Singapore
HNDM proceedings of November 2016,Singapore
Global R & D Services
B3SC proceedings of November 2016,Singapore
B3SC proceedings of November 2016,Singapore
Global R & D Services
2008.02.12 Massie Hyperlipidemia
2008.02.12 Massie Hyperlipidemia
MedicineAndHealthCancer
Intensive Insulin Therapy In The Medical ICU
Intensive Insulin Therapy In The Medical ICU
Muhammad Badawi
April journal watch
April journal watch
katejohnpunag
Journal club: Cardiovascular Disease
Journal club: Cardiovascular Disease
CCNM
Pre hospital reduced-dose fibrinolysis followed by pci
Pre hospital reduced-dose fibrinolysis followed by pci
Vishwanath Hesarur
AFFIRM trial JC NOVANT
AFFIRM trial JC NOVANT
Elmira Darvish
Exeter Drugs Update
Exeter Drugs Update
PeninsulaEndocrine
Nejmoa1507688 (1) (1)
Nejmoa1507688 (1) (1)
Dniz Mejillitaz
More Related Content
What's hot
Journal club 20 10-2016
Journal club 20 10-2016
Amit Verma
RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...
RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...
Sociedad Latinoamericana de Cardiología Intervencionista
Nov journal watch
Nov journal watch
katejohnpunag
Chest pain scores
Chest pain scores
Kristopher Maday
Journal club 1
Journal club 1
Bhargav Kiran
Ascend trial diabetes
Ascend trial diabetes
SATYA PRASAD Mahapatra
Journal club on Antiypertensives
Journal club on Antiypertensives
Dr.Kiran A Kantanavar
Feb 2015 journal watch with links
Feb 2015 journal watch with links
katejohnpunag
Journal club
Journal club
STANMED
Journal club
Journal club
LPS Institute of Cardiology Kanpur UP India
Heparin with ua
Heparin with ua
Virginia Mason Internal Medicine Residency
Intensive Insulin Therapy In The Medical Icu
Intensive Insulin Therapy In The Medical Icu
NadSamm
HNDM proceedings of November 2016,Singapore
HNDM proceedings of November 2016,Singapore
Global R & D Services
B3SC proceedings of November 2016,Singapore
B3SC proceedings of November 2016,Singapore
Global R & D Services
2008.02.12 Massie Hyperlipidemia
2008.02.12 Massie Hyperlipidemia
MedicineAndHealthCancer
Intensive Insulin Therapy In The Medical ICU
Intensive Insulin Therapy In The Medical ICU
Muhammad Badawi
April journal watch
April journal watch
katejohnpunag
Journal club: Cardiovascular Disease
Journal club: Cardiovascular Disease
CCNM
Pre hospital reduced-dose fibrinolysis followed by pci
Pre hospital reduced-dose fibrinolysis followed by pci
Vishwanath Hesarur
AFFIRM trial JC NOVANT
AFFIRM trial JC NOVANT
Elmira Darvish
What's hot
(20)
Journal club 20 10-2016
Journal club 20 10-2016
RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...
RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...
Nov journal watch
Nov journal watch
Chest pain scores
Chest pain scores
Journal club 1
Journal club 1
Ascend trial diabetes
Ascend trial diabetes
Journal club on Antiypertensives
Journal club on Antiypertensives
Feb 2015 journal watch with links
Feb 2015 journal watch with links
Journal club
Journal club
Journal club
Journal club
Heparin with ua
Heparin with ua
Intensive Insulin Therapy In The Medical Icu
Intensive Insulin Therapy In The Medical Icu
HNDM proceedings of November 2016,Singapore
HNDM proceedings of November 2016,Singapore
B3SC proceedings of November 2016,Singapore
B3SC proceedings of November 2016,Singapore
2008.02.12 Massie Hyperlipidemia
2008.02.12 Massie Hyperlipidemia
Intensive Insulin Therapy In The Medical ICU
Intensive Insulin Therapy In The Medical ICU
April journal watch
April journal watch
Journal club: Cardiovascular Disease
Journal club: Cardiovascular Disease
Pre hospital reduced-dose fibrinolysis followed by pci
Pre hospital reduced-dose fibrinolysis followed by pci
AFFIRM trial JC NOVANT
AFFIRM trial JC NOVANT
Similar to Nejm Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
Exeter Drugs Update
Exeter Drugs Update
PeninsulaEndocrine
Nejmoa1507688 (1) (1)
Nejmoa1507688 (1) (1)
Dniz Mejillitaz
American Journal of Emergency & Critical Care Medicine
American Journal of Emergency & Critical Care Medicine
SciRes Literature LLC. | Open Access Journals
Barefoot_McGrath_Oliver_Poster_11032014
Barefoot_McGrath_Oliver_Poster_11032014
Danielle Barefoot
International Study of Comparative Health Effectiveness with Medical and Inva...
International Study of Comparative Health Effectiveness with Medical and Inva...
Chi Pham
Aspirin for primary prevention of CVD
Aspirin for primary prevention of CVD
Pinkesh Parmar
Nrcardio.2014.104
Nrcardio.2014.104
Elsa von Licy
Statin Use Cancer Related Mortality M Wilmath Nov2012 Whh Adult Med
Statin Use Cancer Related Mortality M Wilmath Nov2012 Whh Adult Med
Mario Wilmath
Aas en quirurgicos no cardiaca
Aas en quirurgicos no cardiaca
elmer cordova calle
Sprint 2015 nejm
Sprint 2015 nejm
Juan Sebastian Espinosa-Serna
Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retros...
Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retros...
KhalafAlGhamdi
Screening cáncer próstata, nejm, marzo 2017
Screening cáncer próstata, nejm, marzo 2017
marcela maria morinigo kober
Inter society consensus for the management of peripheral arterial disease (tasc)
Inter society consensus for the management of peripheral arterial disease (tasc)
Jonathan Campos
Transrectal ultrasound guide prostate biopsies in patients taking aspirin for...
Transrectal ultrasound guide prostate biopsies in patients taking aspirin for...
anemo_site
Transrectal ultrasound guided prostate biopsies in patients taking aspirin fo...
Transrectal ultrasound guided prostate biopsies in patients taking aspirin fo...
anemo_site
Comparative effectiveness of acei and arbi
Comparative effectiveness of acei and arbi
Ramachandra Barik
Overuse of Stress Ulcer prophylaxis (SUP)
Overuse of Stress Ulcer prophylaxis (SUP)
Neveen Karima
The vanish rabdomized clinical trial jama 2016 (1)
The vanish rabdomized clinical trial jama 2016 (1)
Roo Motta Figueroa
Acute coronary syndrome
Acute coronary syndrome
MedicinaIngles
update in dual antiplatlet 2018.ppt
update in dual antiplatlet 2018.ppt
AdelSALLAM4
Similar to Nejm Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
(20)
Exeter Drugs Update
Exeter Drugs Update
Nejmoa1507688 (1) (1)
Nejmoa1507688 (1) (1)
American Journal of Emergency & Critical Care Medicine
American Journal of Emergency & Critical Care Medicine
Barefoot_McGrath_Oliver_Poster_11032014
Barefoot_McGrath_Oliver_Poster_11032014
International Study of Comparative Health Effectiveness with Medical and Inva...
International Study of Comparative Health Effectiveness with Medical and Inva...
Aspirin for primary prevention of CVD
Aspirin for primary prevention of CVD
Nrcardio.2014.104
Nrcardio.2014.104
Statin Use Cancer Related Mortality M Wilmath Nov2012 Whh Adult Med
Statin Use Cancer Related Mortality M Wilmath Nov2012 Whh Adult Med
Aas en quirurgicos no cardiaca
Aas en quirurgicos no cardiaca
Sprint 2015 nejm
Sprint 2015 nejm
Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retros...
Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retros...
Screening cáncer próstata, nejm, marzo 2017
Screening cáncer próstata, nejm, marzo 2017
Inter society consensus for the management of peripheral arterial disease (tasc)
Inter society consensus for the management of peripheral arterial disease (tasc)
Transrectal ultrasound guide prostate biopsies in patients taking aspirin for...
Transrectal ultrasound guide prostate biopsies in patients taking aspirin for...
Transrectal ultrasound guided prostate biopsies in patients taking aspirin fo...
Transrectal ultrasound guided prostate biopsies in patients taking aspirin fo...
Comparative effectiveness of acei and arbi
Comparative effectiveness of acei and arbi
Overuse of Stress Ulcer prophylaxis (SUP)
Overuse of Stress Ulcer prophylaxis (SUP)
The vanish rabdomized clinical trial jama 2016 (1)
The vanish rabdomized clinical trial jama 2016 (1)
Acute coronary syndrome
Acute coronary syndrome
update in dual antiplatlet 2018.ppt
update in dual antiplatlet 2018.ppt
More from Bhargav Kiran
Vitamin d and heart disease
Vitamin d and heart disease
Bhargav Kiran
Cardiovascular system
Cardiovascular system
Bhargav Kiran
Aphasia & memory loss
Aphasia & memory loss
Bhargav Kiran
Cvs & rs symptoms
Cvs & rs symptoms
Bhargav Kiran
Journal smart trial 09 08 18
Journal smart trial 09 08 18
Bhargav Kiran
Acute encephalitis suresh ppt
Acute encephalitis suresh ppt
Bhargav Kiran
Fuo
Fuo
Bhargav Kiran
Att induced hepatitis.pptx new
Att induced hepatitis.pptx new
Bhargav Kiran
Recent changes in behavior of plasmodium
Recent changes in behavior of plasmodium
Bhargav Kiran
Saf presentation
Saf presentation
Bhargav Kiran
Cardiactumors 100910174533-phpapp02
Cardiactumors 100910174533-phpapp02
Bhargav Kiran
Approach to murmurs
Approach to murmurs
Bhargav Kiran
Insulin analogues
Insulin analogues
Bhargav Kiran
2 normalmetabolismofwaterandsodium
2 normalmetabolismofwaterandsodium
Bhargav Kiran
Clinico pathological case presentation
Clinico pathological case presentation
Bhargav Kiran
Approach to bradyarrythmias1
Approach to bradyarrythmias1
Bhargav Kiran
Latest edition tog updates
Latest edition tog updates
Bhargav Kiran
Approach to thrombosis_gow_edit (1)
Approach to thrombosis_gow_edit (1)
Bhargav Kiran
New sickle copy
New sickle copy
Bhargav Kiran
Aortic dissctn
Aortic dissctn
Bhargav Kiran
More from Bhargav Kiran
(20)
Vitamin d and heart disease
Vitamin d and heart disease
Cardiovascular system
Cardiovascular system
Aphasia & memory loss
Aphasia & memory loss
Cvs & rs symptoms
Cvs & rs symptoms
Journal smart trial 09 08 18
Journal smart trial 09 08 18
Acute encephalitis suresh ppt
Acute encephalitis suresh ppt
Fuo
Fuo
Att induced hepatitis.pptx new
Att induced hepatitis.pptx new
Recent changes in behavior of plasmodium
Recent changes in behavior of plasmodium
Saf presentation
Saf presentation
Cardiactumors 100910174533-phpapp02
Cardiactumors 100910174533-phpapp02
Approach to murmurs
Approach to murmurs
Insulin analogues
Insulin analogues
2 normalmetabolismofwaterandsodium
2 normalmetabolismofwaterandsodium
Clinico pathological case presentation
Clinico pathological case presentation
Approach to bradyarrythmias1
Approach to bradyarrythmias1
Latest edition tog updates
Latest edition tog updates
Approach to thrombosis_gow_edit (1)
Approach to thrombosis_gow_edit (1)
New sickle copy
New sickle copy
Aortic dissctn
Aortic dissctn
Recently uploaded
Call Girls Thane Just Call 9910780858 Get High Class Call Girls Service
Call Girls Thane Just Call 9910780858 Get High Class Call Girls Service
sonalikaur4
Housewife Call Girls Bangalore - Call 7001305949 Rs-3500 with A/C Room Cash o...
Housewife Call Girls Bangalore - Call 7001305949 Rs-3500 with A/C Room Cash o...
narwatsonia7
sauth delhi call girls in Bhajanpura 🔝 9953056974 🔝 escort Service
sauth delhi call girls in Bhajanpura 🔝 9953056974 🔝 escort Service
9953056974 Low Rate Call Girls In Saket, Delhi NCR
Escort Service Call Girls In Sarita Vihar,, 99530°56974 Delhi NCR
Escort Service Call Girls In Sarita Vihar,, 99530°56974 Delhi NCR
9953056974 Low Rate Call Girls In Saket, Delhi NCR
Call Girl Bangalore Nandini 7001305949 Independent Escort Service Bangalore
Call Girl Bangalore Nandini 7001305949 Independent Escort Service Bangalore
narwatsonia7
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptx
Dr.Nusrat Tariq
Asthma Review - GINA guidelines summary 2024
Asthma Review - GINA guidelines summary 2024
Gabriel Guevara MD
Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...
Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...
narwatsonia7
Call Girls Electronic City Just Call 7001305949 Top Class Call Girl Service A...
Call Girls Electronic City Just Call 7001305949 Top Class Call Girl Service A...
narwatsonia7
Call Girl Service Bidadi - For 7001305949 Cheap & Best with original Photos
Call Girl Service Bidadi - For 7001305949 Cheap & Best with original Photos
narwatsonia7
Call Girls Hsr Layout Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hsr Layout Just Call 7001305949 Top Class Call Girl Service Available
narwatsonia7
Hemostasis Physiology and Clinical correlations by Dr Faiza.pdf
Hemostasis Physiology and Clinical correlations by Dr Faiza.pdf
MedicoseAcademics
Call Girls In Andheri East Call 9920874524 Book Hot And Sexy Girls
Call Girls In Andheri East Call 9920874524 Book Hot And Sexy Girls
nehamumbai
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Available
narwatsonia7
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
narwatsonia7
Low Rate Call Girls Mumbai Suman 9910780858 Independent Escort Service Mumbai
Low Rate Call Girls Mumbai Suman 9910780858 Independent Escort Service Mumbai
sonalikaur4
VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...
VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...
Miss joya
Call Girls Service Nandiambakkam | 7001305949 At Low Cost Cash Payment Booking
Call Girls Service Nandiambakkam | 7001305949 At Low Cost Cash Payment Booking
Nehru place Escorts
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
narwatsonia7
Aspirin presentation slides by Dr. Rewas Ali
Aspirin presentation slides by Dr. Rewas Ali
RewAs ALI
Recently uploaded
(20)
Call Girls Thane Just Call 9910780858 Get High Class Call Girls Service
Call Girls Thane Just Call 9910780858 Get High Class Call Girls Service
Housewife Call Girls Bangalore - Call 7001305949 Rs-3500 with A/C Room Cash o...
Housewife Call Girls Bangalore - Call 7001305949 Rs-3500 with A/C Room Cash o...
sauth delhi call girls in Bhajanpura 🔝 9953056974 🔝 escort Service
sauth delhi call girls in Bhajanpura 🔝 9953056974 🔝 escort Service
Escort Service Call Girls In Sarita Vihar,, 99530°56974 Delhi NCR
Escort Service Call Girls In Sarita Vihar,, 99530°56974 Delhi NCR
Call Girl Bangalore Nandini 7001305949 Independent Escort Service Bangalore
Call Girl Bangalore Nandini 7001305949 Independent Escort Service Bangalore
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptx
Asthma Review - GINA guidelines summary 2024
Asthma Review - GINA guidelines summary 2024
Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...
Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...
Call Girls Electronic City Just Call 7001305949 Top Class Call Girl Service A...
Call Girls Electronic City Just Call 7001305949 Top Class Call Girl Service A...
Call Girl Service Bidadi - For 7001305949 Cheap & Best with original Photos
Call Girl Service Bidadi - For 7001305949 Cheap & Best with original Photos
Call Girls Hsr Layout Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hsr Layout Just Call 7001305949 Top Class Call Girl Service Available
Hemostasis Physiology and Clinical correlations by Dr Faiza.pdf
Hemostasis Physiology and Clinical correlations by Dr Faiza.pdf
Call Girls In Andheri East Call 9920874524 Book Hot And Sexy Girls
Call Girls In Andheri East Call 9920874524 Book Hot And Sexy Girls
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Available
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
Low Rate Call Girls Mumbai Suman 9910780858 Independent Escort Service Mumbai
Low Rate Call Girls Mumbai Suman 9910780858 Independent Escort Service Mumbai
VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...
VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...
Call Girls Service Nandiambakkam | 7001305949 At Low Cost Cash Payment Booking
Call Girls Service Nandiambakkam | 7001305949 At Low Cost Cash Payment Booking
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Aspirin presentation slides by Dr. Rewas Ali
Aspirin presentation slides by Dr. Rewas Ali
Nejm Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
1.
The new engl
and jour nal of medicine n engl j med 379;16 nejm.org October 18, 2018 1529 The members of the writing committee (Louise Bowman, M.D., Marion Mafham, M.D., Karl Wallendszus, M.Sc., Will Ste- vens, Ph.D., Georgina Buck, M.Sc., Jill Barton, Kevin Murphy, Theingi Aung, M.D., Richard Haynes, D.M., Jolyon Cox, D.Phil., Aleksandra Murawska, M.Sc., Al- len Young, Ph.D., Michael Lay, D.Phil., Fang Chen, M.D., Ph.D., Emily Sammons, M.B., Ch.B., Emma Waters, M.B., B.S., Amanda Adler, M.D., Ph.D., Jonathan Bo- dansky, M.D., Andrew Farmer, D.M., Roger McPherson, B.M., F.R.C.Ophth., Andrew Neil, D.Sc., F.R.C.P., David Simp- son, Richard Peto, F.R.S., F.Med.Sci., Co- lin Baigent, F.F.P.H., F.R.C.P., Rory Collins, F.R.S., F.Med.Sci., Sarah Parish, D.Phil., and Jane Armitage, F.R.C.P., F.F.P.H.) as- sume responsibility for the overall con- tent and integrity of this article. The affili- ations of the members of the writing committee are listed in the Appendix. Address reprint requests to Dr. Armitage at the Medical Research Council, Popula- tion Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, Richard Doll Bldg., Old Road Cam- pus, Roosevelt Dr., Oxford OX3 7LF, United Kingdom, or at ascend@ndph.ox.ac.uk or jane.armitage@ndph.ox.ac.uk. * A complete list of the members of the ASCEND Study Collaborative Group is provided in Supplementary Appendix 1, available at NEJM.org. Drs. Bowman and Mafham and Drs. Collins, Parish, and Armitage contributed equally to this article. This article was published on August 26, 2018, at NEJM.org. N Engl J Med 2018;379:1529-39. DOI: 10.1056/NEJMoa1804988 Copyright © 2018 Massachusetts Medical Society. BACKGROUND Diabetes mellitus is associated with an increased risk of cardiovascular events. Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovas- cular events in patients with diabetes is unclear. METHODS We randomly assigned adults who had diabetes but no evident cardiovascular dis- ease to receive aspirin at a dose of 100 mg daily or matching placebo. The primary efficacy outcome was the first serious vascular event (i.e., myocardial infarction, stroke or transient ischemic attack, or death from any vascular cause, excluding any confirmed intracranial hemorrhage). The primary safety outcome was the first major bleeding event (i.e., intracranial hemorrhage, sight-threatening bleeding event in the eye, gastrointestinal bleeding, or other serious bleeding). Secondary outcomes included gastrointestinal tract cancer. RESULTS A total of 15,480 participants underwent randomization. During a mean follow-up of 7.4 years, serious vascular events occurred in a significantly lower percentage of participants in the aspirin group than in the placebo group (658 participants [8.5%] vs. 743 [9.6%]; rate ratio, 0.88; 95% confidence interval [CI], 0.79 to 0.97; P = 0.01). In contrast, major bleeding events occurred in 314 participants (4.1%) in the aspirin group, as compared with 245 (3.2%) in the placebo group (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P = 0.003), with most of the excess being gastrointesti- nal bleeding and other extracranial bleeding. There was no significant difference between the aspirin group and the placebo group in the incidence of gastrointes- tinal tract cancer (157 participants [2.0%] and 158 [2.0%], respectively) or all cancers (897 [11.6%] and 887 [11.5%]); long-term follow-up for these outcomes is planned. CONCLUSIONS Aspirin use prevented serious vascular events in persons who had diabetes and no evident cardiovascular disease at trial entry, but it also caused major bleeding events. The absolute benefits were largely counterbalanced by the bleeding hazard. (Funded by the British Heart Foundation and others; ASCEND Current Controlled Trials number, ISRCTN60635500; ClinicalTrials.gov number, NCT00135226.) ABSTR ACT Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus The ASCEND Study Collaborative Group* Original Article The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY OF MINNESOTA LIBRARIES on October 21, 2018. For personal use only. No other uses without permission. Copyright © 2018 Massachusetts Medical Society. All rights reserved.
2.
n engl j
med 379;16 nejm.org October 18, 20181530 The new engl and jour nal of medicine I t is well established that aspirin use is beneficial for patients with cardiovascular disease, but it is less clear that there is over- all benefit in persons who have not yet had a cardiovascular event.1,2 Patients with diabetes mellitus have a risk of vascular events that is two to three times as high as the risk among those without diabetes,3 but most of the estimated 400 million persons with diabetes worldwide do not have manifest vascular disease.4 The 2009 Antithrombotic Trialists’ Collabora- tion meta-analysis involving 95,000 patients in six primary prevention trials showed that assign- ment to aspirin use led to a 12% (95% confidence interval [CI], 6 to 18) lower risk of serious vascu- lar events than control.1 On average, however, the approximate 50% higher risk of bleeding with aspirin use than with control counterbalanced much of the benefit in these low-risk patients. Only approximately 4% of participants in those trials had diabetes, and the lower relative risk among them was similar to that observed among participants without diabetes (as was also ob- served in the context of secondary prevention). Likewise, the higher relative risk of bleeding with aspirin use than with control was similar among persons with diabetes and those without diabetes. Since the analyses of the Antithrombotic Tri- alists’ Collaboration, four trials of aspirin use for primary prevention (two specifically involving patients with diabetes5,6 and two in broader popu- lations7,8 ) have been reported; none showed a clear benefit or reported detailed information regarding bleeding events, so the balance of benefits and risks associated with aspirin use for primary pre- vention among persons with diabetes remains uncertain. Partly as a result of these studies, there has been speculation that diabetes may be as- sociated with reduced efficacy of the antiplatelet effects of aspirin.9 Retrospective meta-analyses of selected ran- domized trials of mainly low-dose aspirin have suggested that aspirin use may result in an inci- dence of cancer or death from cancer that is 15 to 20% lower than that with control.10-13 In particu- lar, reductions of 30 to 40% in the incidence of gastrointestinal cancers (particularly colorectal cancer) were observed, with the effects appearing to increase with more prolonged exposure and with longer follow-up up to 20 years. Data from randomized trials of sufficient size and duration will be useful in assessing any effects of aspirin use on cancer more reliably. We performed the ASCEND (A Study of Cardiovascular Events in Dia- betes) randomized trial to assess the efficacy and safety of enteric-coated aspirin at a dose of 100 mg daily, as compared with placebo, in persons who had diabetes without manifest cardiovascular disease at trial entry. Using a factorial design in the same trial, we also randomly assigned the pa- tients to receive a daily regimen of either n−3 fatty acids, administered as 1-g capsules, or placebo, findings that are now reported elsewhere in the Journal.14 Methods Trial Oversight ASCEND was designed and conducted by inde- pendent investigators in the Clinical Trial Service Unit at the University of Oxford (the regulatory trial sponsor). The trial methods, characteristics of the participants, and data analysis plan (including outcome definitions) have been reported previ- ously.15,16 The protocol (available with the full text of this article at NEJM.org) was approved by the North West Multicenter Research Ethics Com- mittee. The trial was funded by the British Heart Foundation. The aspirin and matching placebo (along with funding for packaging) were pro- vided by Bayer (Germany), and Solvay, Abbott, and Mylan provided the n−3 fatty acid and pla- cebo capsules and some funding for packaging. Bayer (Germany) commented on the design of the trial, and both Bayer and Mylan commented on the draft of the manuscript but had no part in the collection, handling, analysis, or interpretation of the data or in the decision to submit the manu- script for publication. The manuscript was pre- pared by the writing committee and reviewed and approved for submission for publication by the steering committee. The first and last members of the writing committee vouch for the accuracy and completeness of the data and analyses and for the fidelity of the trial to the protocol and the data analysis plan. Data Sharing Deidentified data about the individual participants are to be shared with the Antithrombotic Trialists’ Collaboration for meta-analysis. Requests for data sharing will be handled in line with the data ac- cess and sharing policy of the Nuffield Depart- A Quick Take is available at NEJM.org The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY OF MINNESOTA LIBRARIES on October 21, 2018. For personal use only. No other uses without permission. Copyright © 2018 Massachusetts Medical Society. All rights reserved.
3.
n engl j
med 379;16 nejm.org October 18, 2018 1531 Aspirin for Primary Prevention in Diabetes Mellitus ment of Population Health, University of Oxford (www.ndph.ox.ac.uk/about/data-access-policy). Participants Men and women at least 40 years of age were considered to be eligible if they had received a diagnosis of diabetes mellitus (any type) and did not have known cardiovascular disease and if there was substantial uncertainty about whether antiplatelet therapy would confer worthwhile ben- efit. Key exclusion criteria were a clear indication for aspirin or a contraindication to aspirin or the presence of other clinically significant conditions that might limit adherence to the trial regimen for at least 5 years. All the participants provided written informed consent. Procedures Potential participants were identified from re- gional diabetes registers or general practices from around the United Kingdom and were sent a screening questionnaire. Those who returned the questionnaire indicating that they were willing and eligible to participate entered a prerandom- ization run-in phase, during which placebo aspi- rin (and placebo n−3 fatty acids) was supplied. Their family doctor was informed of their poten- tial participation, and they were sent a kit to ob- tain blood and urine samples and to record blood pressure, height, and weight. After this run-in period of 8 to 10 weeks, participants remained eligible if they returned a randomization ques- tionnaire confirming their willingness to continue, they still met the eligibility criteria, and they had adhered to the trial regimen. Using minimized randomization, we then as- signed eligible participants to receive 100 mg of aspirin once daily or a matching placebo tablet16 ; participants were also assigned to receive 1-g cap- sules containing n−3 fatty acid once daily or a matching placebo capsule. The participants were then mailed a 6-month supply of aspirin or placebo tablets and n−3 fatty acids or placebo capsules, as appropriate. After randomization, we sent follow-up ques- tionnaires and appropriate tablets and capsules to participants every 6 months until the end of the trial. In these questionnaires, we sought informa- tion regarding all serious adverse events (including potential trial outcomes), adherence to the trial regimen, use of nontrial antiplatelet or anticoagu- lant therapy, nonserious adverse events resulting in discontinuation of the trial regimen, and any symptomatic bleeding episodes for which patients saw a doctor. After a mean follow-up of 2.5 years, we requested blood and urine samples, along with measures of blood pressure and weight, from 1800 randomly selected participants. (Details are provided in the Methods section in Supplemen- tary Appendix 1, available at NEJM.org.) Outcomes While recruitment was still ongoing, we modified the original primary outcome to include transient ischemic attack in the definition of serious vascu- lar event, a change that was made to increase the statistical power of the trial. Thus, the prespeci- fied primary efficacy outcome was the first seri- ous vascular event, which was defined as a com- posite of nonfatal myocardial infarction, nonfatal stroke (excluding confirmed intracranial hemor- rhage) or transient ischemic attack, or death from any vascular cause (excluding confirmed intracra- nial hemorrhage). The primary safety outcome was the first occurrence of any major bleeding event, which was defined as a composite of any confirmed intracranial hemorrhage, sight-threat- ening bleeding event in the eye, gastrointestinal bleeding, or any other serious bleeding (i.e., a bleeding event that resulted in hospitalization or transfusion or that was fatal). Secondary outcomes were gastrointestinal tract cancer (overall and ex- cluding those occurring during the first 3 years of follow-up) and the composite of any serious vascular event or any arterial revascularization procedure. All the reports of possible primary or second- ary outcomes were adjudicated centrally by clini- cians who were unaware of the trial-group assign- ments in accordance with prespecified definitions. The data analysis plan prespecified that analyses would be based on all the confirmed events plus unrefuted events (see the Methods section in Sup- plementary Appendix 1). Statistical Analysis The data analysis plan was finalized by the steer- ing committee and was published16 while all the members were still unaware of the trial results according to group assignment (except for the statistician, who was aware of these assignments and who was not involved in development of the data analysis plan). In addition to revising the definition of serious vascular events to include The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY OF MINNESOTA LIBRARIES on October 21, 2018. For personal use only. No other uses without permission. Copyright © 2018 Massachusetts Medical Society. All rights reserved.
4.
n engl j
med 379;16 nejm.org October 18, 20181532 The new engl and jour nal of medicine transient ischemic attack, the sample was in- creased to at least 15,000 participants and the duration of follow-up was increased to at least 7 years to increase the power of the trial. (Details are provided in the Methods section in Supple- mentary Appendix 1.) On the basis of an event rate of 1.2 to 1.3% per year, as observed in both groups combined when recruitment was complete, we determined that 7.5 years of the scheduled trial regimen would provide the trial with 90% power, at a P value of less than 0.05, to detect a 15% difference between the treatment groups in the risk of a serious vas- cular event. The expected number of gastrointes- tinal tract cancers was estimated to provide the trial with 60% power to detect a 30% lower risk in the aspirin group than in the placebo group during this period, but the prespecified focus for assessing the effects on cancer is 5 and 10 years after the end of the scheduled intervention phase. We used log-rank methods to conduct inten- tion-to-treat comparisons in time-to-event analy- ses of the first occurrence of each type of event of interest among participants in the aspirin group as compared with those in the placebo group.17,18 A two-tailed P value of less than 0.05 was consid- ered to indicate statistical significance for the primary efficacy and safety outcomes. It was prespecified that the combined secondary out- come of serious vascular event or revasculariza- tion would be used for any subgroup analyses. We made allowance for multiple hypothesis test- ing in the interpretation of secondary and explor- atory outcomes, with no formal adjustment to the P values. Consequently, the results are reported as point estimates and 95% confidence intervals that have not been adjusted for multiple com- parisons, so the confidence intervals should not be used to infer definitive treatment effects within subgroups or with regard to secondary outcomes. The baseline 5-year risk of vascular events among participants was categorized into three groups — less than 5%, 5% to less than 10%, and 10% or more — with the use of a risk score that had been developed with the use of Poisson regression. Details regarding this and other sec- ondary and exploratory assessments are provid- ed in the data analysis plan16 and in Supplemen- tary Appendix 1. The Clinical Trial Service Unit at the University of Oxford holds the full data- base and performed all the analyses. Results Trial Participants From June 2005 through July 2011, a total of 15,480 participants underwent randomization. The main prognostic characteristics of the par- ticipants were well balanced between the ran- domized groups (Table 1, and Tables S1 and S2 in Supplementary Appendix 1). Aspirin use be- fore screening was reported by 5508 participants overall (35.6%), but the treating doctor and the participant were sufficiently uncertain about its value to agree to randomization between aspirin and placebo. At the end of the scheduled follow-up period, complete follow-up data were available for 15,341 participants (99.1%) who had undergone ran- domization (Fig. S1 and Table S3 in Supplemen- tary Appendix 1). The mean follow-up was 7.4 years, which yielded 57,000 person-years in the aspirin group and 56,945 person-years in the placebo group. Adjudication was complete for more than 90% of the primary and secondary outcomes. Adherence and Effects on Vascular Risk Factors The estimated mean adherence (weighted accord- ing to person-years at risk for a serious vascular event) to the assigned regimen was 70% in the aspirin group and 70% in the placebo group. Dur- ing follow-up, adherence to the aspirin regimen declined while the use of nontrial aspirin and other antiplatelet treatment increased. The esti- mated mean between-group difference in the rate of use of trial aspirin or nontrial aspirin or other antiplatelet treatment was 69 percentage points (Table S4 in Supplementary Appendix 1). The reasons for discontinuation of the trial regimen are shown in Table S5 in Supplementary Appen- dix 1. The use of nontrial medications (as reported at randomization and after a mean follow-up of 6.7 years) was similar in the two groups (Table S6 in Supplementary Appendix 1). Table S7 in Supplementary Appendix 1 shows data regarding various vascular risk factors at a mean of 2.5 years after randomization in the se- lected subgroup of approximately 1000 partici- pants who were broadly representative of the trial population. Findings were similar in the two trial groups except for small differences in the systolic blood pressure and the estimated glomerular fil- The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY OF MINNESOTA LIBRARIES on October 21, 2018. For personal use only. No other uses without permission. Copyright © 2018 Massachusetts Medical Society. All rights reserved.
5.
n engl j
med 379;16 nejm.org October 18, 2018 1533 Aspirin for Primary Prevention in Diabetes Mellitus Characteristic Aspirin Group (N = 7740) Placebo Group (N = 7740) Age Mean — yr 63.2±9.2 63.3±9.2 Distribution — no. (%) <60 yr 2795 (36.1) 2795 (36.1) 60 to <70 yr 3123 (40.3) 3124 (40.4) ≥70 yr 1822 (23.5) 1821 (23.5) Male sex — no. (%) 4843 (62.6) 4841 (62.5) White race — no. (%)† 7467 (96.5) 7468 (96.5) Body-mass index‡ Mean 30.8±6.2 30.6±6.3 Distribution — no. (%) <25 1080 (14.0) 1169 (15.1) 25 to <30 2753 (35.6) 2776 (35.9) ≥30 3665 (47.4) 3536 (45.7) Unknown 242 (3.1) 259 (3.3) Smoking status — no. (%) Current smoker 639 (8.3) 640 (8.3) Former smoker 3526 (45.6) 3525 (45.5) Never smoked 3489 (45.1) 3488 (45.1) Unknown 86 (1.1) 87 (1.1) Participant-reported hypertension — no. (%) 4766 (61.6) 4767 (61.6) Aspirin use before screening — no. (%) 2740 (35.4) 2768 (35.8) Statin use — no. (%) 5854 (75.6) 5799 (74.9) Type 2 diabetes — no. (%)§ 7282 (94.1) 7287 (94.1) Duration of diabetes Median (interquartile range) — yr 7 (3–13) 7 (3–13) Distribution — no. (%) <9 yr 4337 (56.0) 4322 (55.8) ≥9 yr 2976 (38.4) 2989 (38.6) Unknown 427 (5.5) 429 (5.5) Systolic blood pressure Mean — mm Hg 136.1±15.2 136.2±15.3 Distribution — no. (%) <130 mm Hg 1694 (21.9) 1700 (22.0) ≥130 to <140 mm Hg 1550 (20.0) 1541 (19.9) ≥140 mm Hg 2263 (29.2) 2292 (29.6) Unknown 2233 (28.9) 2207 (28.5) Vascular risk score — no. (%)¶ Low 3128 (40.4) 3136 (40.5) Moderate 3294 (42.6) 3254 (42.0) High 1318 (17.0) 1350 (17.4) * Plus–minus values are means ±SD. Numbers and percentages are shown for categorical variables, and means or medians (with interquartile ranges) for continuous variables. There were no significant differences between the assigned groups. Percentages may not total 100 because of rounding. † Race and ethnic group were reported by the participant. Other groups were Indian, Pakistani, or Bangladeshi (1% of participants), African or Caribbean (1%), and other or unknown (1%). ‡ The body-mass index (the weight in kilograms divided by the square of the height in meters) was based on values for height and weight that were reported by the participants. § The presence of type 2 diabetes was based on a broad clinical definition involving the age of the participant at the diag- nosis of diabetes, the use of insulin within 1 year after diagnosis, and the body-mass index. ¶ We categorized the predicted 5-year risk of serious vascular event (including transient ischemic attack) without the use of aspi- rin or n−3 fatty acids as follows: low risk as less than 5%, moderate risk as 5% to less than 10%, and high risk as 10% or more. Table 1. Key Characteristics of the Participants at Baseline.* The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY OF MINNESOTA LIBRARIES on October 21, 2018. For personal use only. No other uses without permission. Copyright © 2018 Massachusetts Medical Society. All rights reserved.
6.
n engl j
med 379;16 nejm.org October 18, 20181534 The new engl and jour nal of medicine tration rate, which may well be chance findings given the multiple comparisons. Effects on the Primary and Secondary Vascular Outcomes During the scheduled intervention period, the primary efficacy outcome occurred in a signifi- cantly lower percentage of participants in the as- pirin group than in the placebo group (658 [8.5%] vs. 743 [9.6%]; rate ratio, 0.88; 95% CI, 0.79 to 0.97; P = 0.01) (Fig. 1A). In exploratory analyses, the risk difference was seen mainly in the first 5 years, with no further gain subse- quently in the number of participants avoiding an event (Fig. 1B). The effects on the components of the primary efficacy outcome and the second- ary outcome of serious vascular event or any arterial revascularization are shown in Figure 2. Prespecified exploratory analyses showed no sig- nificant effect of aspirin use, as compared with placebo, on the rate of death from all vascular causes combined, which represented approximate- ly 30% of all deaths (Fig. S2 in Supplementary Appendix 1). Effects on the Primary Safety Outcome and Other Bleeding There was a significant adverse effect of assign- ment to the aspirin group, as compared with the placebo group, on the incidence of major bleeding (314 participants [4.1%] vs. 245 [3.2%]; rate ratio, 1.29; 95% CI, 1.09 to 1.52; P = 0.003) (Fig. 2). Ex- ploratory analyses did not suggest an attenua- tion of the effect on bleeding over time (Fig. S3 in Supplementary Appendix 1). Of the first major bleeding events, 41.3% were gastrointestinal (of which 62.3% were in the upper gastrointestinal tract, 32.9% were in the lower gastrointestinal tract, 2.2% were perforations, and 2.6% were undetermined), 21.1% were sight-threatening bleeding events in the eye, 17.2% were intracra- nial bleeding events, and 20.4% were bleeding events in other sites (mainly hematuria and epi- staxis that met the definition of major bleeding). The incidence of fatal bleeding events was simi- lar among persons in the aspirin group and among those in the placebo group (19 partici- pants [0.2%] and 16 [0.2%], respectively), as was the incidence of hemorrhagic stroke (25 [0.3%] and 26 [0.3%]) (Table S8 in Supplementary Ap- pendix 1). Effects on Vascular Events and Bleeding According to Baseline Characteristics In exploratory analyses, the proportional effects of aspirin use on the combined outcome of seri- ous vascular events or revascularization and on the safety outcome of major bleeding did not show clear evidence of variation according to particular baseline characteristics (with allowance for multi- ple comparisons). In particular, neither outcome varied according to group assignment with re- gard to n−3 fatty acids or to the vascular risk group at baseline (Figs. S4 and S5 in Supplemen- tary Appendix 1). Figure 3 shows that the inci- dence of a major bleeding event increased with vascular risk. Substantial uncertainty around the observed number of events caused and avoided results from small numbers and differences in adherence. Figure S6 in Supplementary Appendix 1 shows the predicted absolute effects with extrap- olation to full adherence to the trial regimen. Effects on Other Vascular and Microvascular Outcomes Results of exploratory analyses of the effects of aspirin use on other vascular and selected micro- vascular outcomes are shown in Figure S7 and Table S9 in Supplementary Appendix 1. The re- sults regarding the vascular events show trends that are generally similar to those regarding se- rious vascular events. There was no apparent effect of aspirin use on selected microvascular events. Effects on Cancer and Other Nonvascular Outcomes There was no between-group difference in the risk of gastrointestinal tract cancer, nor was there a suggestion of an effect emerging with longer follow-up (Fig. S8 in Supplementary Appendix 1). The trial groups also did not differ significantly with regard to the risk of fatal or nonfatal cancer overall or at particular sites (Table 2, and Fig. S9 in Supplementary Appendix 1) or with regard to the risks of death overall or death from cancer or from all nonvascular causes (Fig. S2 in Sup- plementary Appendix 1). Searchable tabulations of the serious adverse events (fatal and nonfatal combined) are provided in Supplementary Appen- dix 2, available at NEJM.org. They are grouped on the basis of the Medical Dictionary for Regulatory Activities, version 14.0, classification system, ac- cording to system organ class. The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY OF MINNESOTA LIBRARIES on October 21, 2018. For personal use only. No other uses without permission. Copyright © 2018 Massachusetts Medical Society. All rights reserved.
7.
n engl j
med 379;16 nejm.org October 18, 2018 1535 Aspirin for Primary Prevention in Diabetes Mellitus Discussion In this trial involving persons who had diabetes without manifest cardiovascular disease, assign- ment to the use of aspirin at a dose of 100 mg daily for 7.4 years resulted in a risk of serious vascular events that was 12% lower than that with placebo but also in a risk of major bleeding that Figure 1. First Serious Vascular Event during Follow-up. Panel A shows a Kaplan–Meier plot of the first serious vascular event (a composite of nonfatal myocardial infarction, nonfatal ischemic stroke or transient ischemic attack, or death from any vascular cause, excluding confirmed intra- cranial hemorrhage) during follow-up. The numbers of participants at risk at the start of each year of follow-up are shown, along with the cumulative number (±SE) of participants per 1000 in the aspirin group as compared with the placebo group who avoided events. The inset shows the same data on an expanded y axis. Panel B shows the rate ratios for the first serious vascular event among the participants in the aspirin group, as compared with those in the placebo group, according to the period of follow-up. The numbers at risk declined with each period of follow-up be- cause of censoring, so the percentages are the number of events as a proportion of the number at risk at the start of each period. For each period of follow-up, rate ratios are plotted as squares, with the size of each square proportional to the amount of statistical information that was available; the horizontal lines represent 95% confidence intervals (not ad- justed for multiple comparisons), and the dashed vertical line indicates the overall rate ratio for the effect of aspirin use on the first serious vascular event. For the prespecified composite period of follow-up, the rate ratio and corre- sponding 95% confidence interval are represented by a diamond. Squares or a diamond to the left of the solid vertical line indicate a benefit with aspirin use, but the comparison was significant (P0.05) only if the horizontal line or diamond does not overlap with the solid vertical line. The test for trend across years was significant (χ2 = 6.24; P = 0.01). ParticipantswithEvent(%) 100 80 90 70 60 40 30 10 50 20 0 0 1 2 3 4 5 9 Years of Follow-up B First Serious Vascular Event, According to Year of Follow-up A First Serious Vascular Event Rate ratio, 0.88 (95% CI, 0.79–0.97) P=0.01 No. at Risk Placebo Aspirin Cumulative benefit per 1000 participants in aspirin group 7740 7740 4±2 6±2 9±3 10±3 13±4 11±4 12±5 9±6 10±7 7618 7655 7486 7536 7342 7404 7188 7252 7001 7096 6 5771 5825 7 3890 3966 8 15 10 5 0 0 1 2 3 4 5 96 7 8 2200 2222 1430 1428 Placebo Aspirin Year of First Event P Value Aspirin (N=7740) Placebo (N=7740) 201 (2.6) 169 (2.3) 180 (2.5) 108 (2.7) 658 (8.5) 269 (3.5) 198 (2.7) 171 (2.4) 105 (2.7) 743 (9.6) 0.01 0.8 1.0 1.61.41.2 Placebo BetterAspirin Better Rate Ratio (95% CI) 0.74 (0.62–0.89) 0.85 (0.69–1.04) 1.04 (0.84–1.28) 1.02 (0.78–1.33) 0.88 (0.79–0.97) 0.6 no. of participants with event (%) 3 3 to 5 ≥5 to 7 7 All The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY OF MINNESOTA LIBRARIES on October 21, 2018. For personal use only. No other uses without permission. Copyright © 2018 Massachusetts Medical Society. All rights reserved.
8.
n engl j
med 379;16 nejm.org October 18, 20181536 The new engl and jour nal of medicine was 29% higher. The lower risk of serious vascu- lar events is similar to the risk that was reported previously in the Antithrombotic Trialists’ Col- laboration meta-analysis of primary prevention trials of similar doses of aspirin (which used slightly different outcome definitions; see the Methods section in Supplementary Appendix 1).1 In contrast to those previous trials, there were high rates of the use of cardioprotective treat- ments among the participants in ASCEND, with the majority of participants taking statins and blood pressure–lowering therapy. Hence, the pres- ent trial provides a direct assessment of the bal- ance of the benefits and hazards of aspirin use in a contemporary context. In our trial, factors such as the large number of participants and clinical outcomes, long dura- tion of follow-up, the randomized, blinded design of the trial, and the almost complete follow-up of the participants who underwent randomiza- tion have allowed reliable detection of these moderate but important effects on the incidence of vascular events and on both the severity and incidence of bleeding. Our findings do not sup- port the hypothesis that persons with diabetes have a resistance to aspirin.9 Although the pro- portional effects of aspirin use are likely to be generalizable to the wider population of persons with diabetes, the absolute event rates and ad- herence rates reflect this population of persons with well-treated diabetes. Overall, on the basis of the absolute percentage differences between the groups in the incidence of serious vascular events (1.1 percentage points lower in the aspi- rin group than in the placebo group) and in bleeding events (0.9 percentage points higher in the aspirin group), 91 patients would need to be treated to avoid a serious vascular event over a Figure 2. Effect of Assignment to Aspirin Group on Components of Serious Vascular Events, the Combined Outcome of Serious Vascular Event or Revascularization, and Major Bleeding and Its Components. The primary outcome was a serious vascular event (a composite of nonfatal myocardial infarction, nonfatal ischemic stroke or transient ischemic attack [TIA], or death from any vascular cause, excluding confirmed intracranial hemorrhage). Secondary outcomes were a seri- ous vascular event or any coronary or noncoronary revascularization procedure. A single participant may have had multiple events and therefore may contribute information to more than one row. The size of each square for the rate ratio is proportional to the amount of statistical information that was available, the horizontal lines represent 95% confidence intervals, and the dashed vertical line indicates the overall rate ratio for the effect of aspirin use on the first serious vascular event. An arrow on the horizontal line indicates that the confidence interval exceeds the graph area. For composite outcomes, rate ratios and their corresponding 95% confidence intervals are represented by diamonds. Bold entries with diamonds show totals for all data listed above them. The effect of aspirin use on the com- ponents of the primary safety outcome of major bleeding event (a composite of intracranial hemorrhage, sight-threatening bleeding event in the eye, gastrointestinal bleeding, or other major bleeding event) is shown with the use of the same graphic conventions. Type of Event P Value Aspirin (N=7740) Placebo (N=7740) 0.01 0.003 0.7 1.0 2.01.5 Placebo BetterAspirin Better Rate Ratio (95% CI) 0.98 (0.80–1.19) 0.88 (0.73–1.06) 0.91 (0.75–1.10) 0.92 (0.82–1.03) 0.85 (0.69–1.04) 0.88 (0.79–0.97) 0.88 (0.76–1.02) 0.88 (0.80–0.97) 1.22 (0.82–1.81) 0.89 (0.62–1.27) 1.36 (1.05–1.75) 1.70 (1.18–2.44) 1.29 (1.09–1.52) 0.5 no. of participants with event (%) Vascular Outcomes Nonfatal myocardial infarction Nonfatal presumed ischemic stroke Vascular death excluding intracranial hemorrhage Any serious vascular event excluding TIA TIA Any serious vascular event including TIA Any arterial revascularization Any serious vascular event or revascularization Major Bleeding Intracranial hemorrhage Sight-threatening bleeding in eye Serious gastrointestinal bleeding Other major bleeding Any major bleeding 191 (2.5) 202 (2.6) 197 (2.5) 542 (7.0) 168 (2.2) 658 (8.5) 340 (4.4) 833 (10.8) 55 (0.7) 57 (0.7) 137 (1.8) 74 (1.0) 314 (4.1) 195 (2.5) 229 (3.0) 217 (2.8) 587 (7.6) 197 (2.5) 743 (9.6) 384 (5.0) 936 (12.1) 45 (0.6) 64 (0.8) 101 (1.3) 43 (0.6) 245 (3.2) The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY OF MINNESOTA LIBRARIES on October 21, 2018. For personal use only. No other uses without permission. Copyright © 2018 Massachusetts Medical Society. All rights reserved.
9.
n engl j
med 379;16 nejm.org October 18, 2018 1537 Aspirin for Primary Prevention in Diabetes Mellitus period of 7.4 years, and 112 to cause a major bleeding event. These results of intention-to-treat analyses tend to underestimate the effect of actual aspirin use, both with respect to events avoided and bleeding events caused owing to a lack of full adherence to the regimen during the trial. Explor- atory analyses comparing participants at different levels of vascular risk extrapolated the rate ratios in the intention-to-treat analysis to full adherence and assumed that the proportional effects on the incidence of serious vascular events and bleed- ing were the same across different levels of vas- cular risk. The results of these analyses provide a more reliable estimate of the absolute differ- ences in the event rates resulting from aspirin use by applying the extrapolated overall rate ra- tios to the event rates with placebo in each risk group. On the basis of these assumptions, the predicted number of serious vascular events that would be avoided by participants actually taking aspirin was closely balanced by the predicted Figure 3. Observed Absolute Effect of Assignment to Aspirin Group on Serious Vascular Events or Revascularization and on Major Bleeding, According to Vascular Risk. Shown is the observed absolute incidence of serious vascular events or revascularization and of major bleeding events in the aspirin group, as compared with the placebo group, according to the three baseline levels of vascular risk (predicted 5-year risks of a serious vascular event, with low risk defined as 5%, moderate risk as 5% to 10%, and high risk as ≥10%), with data expressed as numbers of events per 5000 person-years. Plus–minus values are means ±SE. Eventsper5000Person-Yr 200 160 180 140 120 80 60 20 100 40 0 Estimated 5-Yr Risk of Serious Vascular Event at Baseline Aspirin Placebo Aspirin Placebo No. of Events per 5000 Person-Yr in Aspirin Group Serious vascular events avoided Serious vascular events or revascularizations avoided Major bleeding caused 5.7±3.7 6.1±4.2 2.8±2.6 11.2±5.4 13.4±6.3 8.9±3.2 4.9±12.9 11.3±14.3 9.6±7.5 Nonfatal myocardial infarction, nonfatal stroke, transient ischemic attack, or revascularization Death from cardiovascular cause Nonfatal major bleeding Fatal bleeding Serious Vascular Event or Revascular- ization Major Bleeding 5% (40.5% of trial population) Aspirin Placebo Aspirin Placebo Serious Vascular Event or Revascular- ization Major Bleeding 5% to 10% (42.3% of trial population) Aspirin Placebo Aspirin Placebo Serious Vascular Event or Revascular- ization Major Bleeding ≥10% (17.2% of trial population) 37.9 44.0 83.5 96.9 28.6 165.1 176.4 54.3 44.7 19.818.1 15.2 The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY OF MINNESOTA LIBRARIES on October 21, 2018. For personal use only. No other uses without permission. Copyright © 2018 Massachusetts Medical Society. All rights reserved.
10.
n engl j
med 379;16 nejm.org October 18, 20181538 The new engl and jour nal of medicine number of major bleeding events caused, even among persons who had a 5-year vascular risk of 10% or more (Fig. S6 in Supplementary Appen- dix 1). A recent analysis suggesting a greater benefit of low-dose aspirin use on the incidence of vascular events among persons with a body weight of less than 70 kg was not confirmed in exploratory subgroup analyses (and, indeed, a trend in the opposite direction was observed).19 The assessment of the balance between the benefit and harm of aspirin use in the context of primary prevention is complicated by the difficulty of comparing the severity of the vascular events avoided and the bleeding events caused. For ex- ample, although transient ischemic attacks are minor in themselves, they are associated with in- creased risks of subsequent stroke and cognitive impairment.20 Approximately half the excess of bleeding was in the gastrointestinal tract, with approximately one third in the upper gastroin- testinal tract. However, even near the end of the trial in 2016, only approximately one quarter of participants were receiving proton-pump inhibi- tors (PPIs). It is possible that bleeding rates among aspirin users might be lower if PPIs were rou- tinely used in these persons, provided that longer- term trials of PPIs21,22 confirm the substantial reductions in the incidence of bleeding in the up- per gastrointestinal tract that has been seen in short-term studies,23 as well as confirming long- term safety. Several meta-analyses of selected randomized trials of generally low-dose aspirin have suggest- ed that aspirin use might reduce the risk of cancer — in particular, gastrointestinal tract cancer — by up to one third during long-term follow-up, with effects becoming apparent approximately 3 years after randomization.10,12,13,24 However, despite more than 7 years of aspirin treatment and follow-up in ASCEND, we found no evidence of a reduction in the incidence of gastrointestinal tract cancer or of cancer at any other site, even during the later years of follow-up. These analyses had limited sta- tistical power to detect the hypothesized effects, so follow-up is being continued through central registries. In conclusion, the use of low-dose aspirin led to a lower risk of serious vascular events than placebo among persons with diabetes who did not have evident cardiovascular disease at trial entry. However, the absolute lower rates of seri- ous vascular events were of similar magnitude to the absolute higher rates of major bleeding, even among participants who had a high vascular risk. The use of low-dose aspirin did not result in a lower risk of gastrointestinal tract cancer or other Cancer Type Aspirin Group (N = 7740) Placebo Group (N = 7740) Rate Ratio (95% CI) no. of participants (%) Gastrointestinal tract cancer 157 (2.0) 158 (2.0) 0.99 (0.80–1.24) Other gastrointestinal cancer† 87 (1.1) 82 (1.1) 1.06 (0.78–1.43) Respiratory cancer 101 (1.3) 103 (1.3) 0.98 (0.74–1.29) Genitourinary cancer 332 (4.3) 294 (3.8) 1.13 (0.97–1.32) Hematologic cancer 88 (1.1) 86 (1.1) 1.02 (0.76–1.38) Breast cancer 97 (1.3) 96 (1.2) 1.01 (0.76–1.34) Melanoma 50 (0.6) 59 (0.8) 0.85 (0.58–1.23) Other cancer 25 (0.3) 30 (0.4) 0.83 (0.49–1.41) Unspecified cancer 26 (0.3) 31 (0.4) 0.84 (0.50–1.41) Any cancer‡ 897 (11.6) 887 (11.5) 1.01 (0.92–1.11) * The 95% confidence intervals were unadjusted for multiple comparisons. A single participant may have had multiple cancers. † Other gastrointestinal cancer includes hepatobiliary and pancreatic cancers. ‡ Any cancer excludes nonfatal nonmelanoma skin cancer and nonfatal recurrence of a cancer that had occurred before randomization. Table 2. Effect of Aspirin Use on the Incidence of Site-Specific Fatal or Nonfatal Cancer.* The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY OF MINNESOTA LIBRARIES on October 21, 2018. For personal use only. No other uses without permission. Copyright © 2018 Massachusetts Medical Society. All rights reserved.
11.
n engl j
med 379;16 nejm.org October 18, 2018 1539 Aspirin for Primary Prevention in Diabetes Mellitus cancer over the mean follow-up of 7.4 years, but further follow-up is needed to assess any longer- term effects on cancer reliably. Supported by grants to the University of Oxford from the Brit- ish Heart Foundation and by Bayer (Germany and the United States), Solvay, Abbott, and Mylan. The Clinical Trial Service Unit at the University of Oxford receives support from the U.K. Medical Research Council (which funds the MRC Population Health Research Unit in a strategic partnership with the Univer- sity of Oxford), the British Heart Foundation, and Cancer Re- search U.K. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. We thank the participants, the collaborating doctors and gen- eral practitioners, the members of the steering committee and the data monitoring committee, and all the administrative and clinical staff who helped to conduct the trial. Appendix The affiliations of the members of the writing committee are as follows: Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health (L.B., M.M., K.W., W.S., G.B., J. Barton, K.M., R.H., J.C., A.M., A.Y., M.L., F.C., E.S., E.W., D.S., R.P., C.B., R.C., S.P., J.A.), Nuffield Department of Primary Care Health Sciences (A.F.), and Wolfson College (A.N.), University of Oxford, Oxford, the Royal Berkshire NHS Foundation Trust, Reading (T.A.), Addenbrooke’s Hospital, Cambridge (A.A.), Leeds General Infirmary, Leeds (J. Bodansky), and University Hospital of Wales, Cardiff (R.M.) — all in the United Kingdom. References 1. Antithrombotic Trialists’ Collabora- tion. Aspirin in the primary and secondary prevention of vascular disease: collabora- tive meta-analysis of individual partici- pant data from randomised trials. Lancet 2009;373:1849-60. 2. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Founda- tion. Circulation 2011;124:2458-73. 3. The Emerging Risk Factors Collabora- tion. Diabetes mellitus, fasting blood glu- cose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375: 2215-22. 4. IDF diabetes atlas. 8th ed. Brussels: International Diabetes Federation, 2017 (http://www.diabetesatlas.org). 5. Belch J, MacCuish A, Campbell I, et al. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in pa- tients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337: a1840. 6. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary pre- vention of atherosclerotic events in pa- tients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134-41. 7. Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese pa- tients 60 years or older with atheroscle- rotic risk factors: a randomized clinical trial. JAMA 2014;312:2510-20. 8. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010;303:841-8. 9. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabeto- logia 2008;51:385-90. 10. Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vas- cular death: analysis of the time course of risks and benefits in 51 randomised con- trolled trials. Lancet 2012;379:1602-12. 11. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorec- tal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lan- cet 2010;376:1741-50. 12. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during ran- domised controlled trials. Lancet 2012; 379:1591-601. 13. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from ran- domised and observational studies. Lancet 2007;369:1603-13. 14. The ASCEND Study Collaborative Group. Effects of n−3 fatty acid supple- ments in diabetes mellitus. N Engl J Med. DOI: 10.1056/NEJMoa1804989. 15. Aung T, Haynes R, Barton J, et al. Cost-effective recruitment methods for a large randomised trial in people with dia- betes: A Study of Cardiovascular Events iN Diabetes (ASCEND). Trials 2016;17:286. 16. Bowman L, Mafham M, Stevens W, et al. ASCEND: A Study of Cardiovascular Events iN Diabetes: characteristics of a randomized trial of aspirin and of ome- ga-3 fatty acid supplementation in 15,480 people with diabetes. Am Heart J 2018; 198:135-44. 17. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71. 18. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clini- cal trials requiring prolonged observation of each patient. I. Introduction and de- sign. Br J Cancer 1976;34:585-612. 19. Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascu- lar events and cancer according to body- weight and dose: analysis of individual patient data from randomised trials. Lan- cet 2018;392:387-99. 20. van Rooij FG, Kessels RPC, Richard E, De Leeuw F-E, van Dijk EJ. Cognitive im- pairment in transient ischemic attack pa- tients: a systematic review. Cerebrovasc Dis 2016;42:1-9. 21. Bosch J, Eikelboom JW, Connolly SJ, et al. Rationale, design and baseline char- acteristics of participants in the Cardio- vascular Outcomes for People Using Anti- coagulation Strategies (COMPASS) trial. Can J Cardiol 2017;33:1027-35. 22. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017;377:1319-30. 23. Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta- analysis of randomised trials. Lancet Gas- troenterol Hepatol 2018;3:231-41. 24. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual pa- tient data from randomised trials. Lancet 2011;377:31-41. Copyright © 2018 Massachusetts Medical Society. The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY OF MINNESOTA LIBRARIES on October 21, 2018. For personal use only. No other uses without permission. Copyright © 2018 Massachusetts Medical Society. All rights reserved.
Download now